CHIP for Human Immunodeficiency Virus (HIV) Infection

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Human Immunodeficiency Virus (HIV) Infection+1 MoreCHIP - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a couples-based HIV prevention program to see if it can reduce the risk of HIV transmission for transgender women and their partners.

Eligible Conditions
  • Human Immunodeficiency Virus (HIV) Infection
  • Primary HIV Infection

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Changes in CR-HIV at 12-month follow-up

Changes in CR-HIV at 12-month follow-up
Composite Risk for HIV

Trial Safety

Trial Design

2 Treatment Groups

Control
1 of 2
Intervention
1 of 2

Active Control

Experimental Treatment

240 Total Participants · 2 Treatment Groups

Primary Treatment: CHIP · No Placebo Group · N/A

Intervention
Behavioral
Experimental Group · 1 Intervention: CHIP · Intervention Types: Behavioral
Control
Behavioral
ActiveComparator Group · 1 Intervention: Control · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: changes in cr-hiv at 12-month follow-up

Who is running the clinical trial?

University of California, San FranciscoOTHER
2,285 Previous Clinical Trials
11,577,677 Total Patients Enrolled
Brown UniversityOTHER
416 Previous Clinical Trials
519,117 Total Patients Enrolled
University of MichiganLead Sponsor
1,634 Previous Clinical Trials
6,415,034 Total Patients Enrolled
Ellen SteinStudy DirectorUniversity of California, San Francisco

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be able to speak and read English.
You are in a romantic relationship for at least three months.
References